Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia.
10.7499/j.issn.1008-8830.2210114
- Author:
Xiao-Lan LI
1
;
Li-Peng LIU
1
;
Fang LIU
1
;
Ye GUO
1
;
Xiao-Juan CHEN
1
;
Xiao-Fan ZHU
1
;
Wen-Yu YANG
1
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Institutes of Health Science, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Blinatumomab;
Child;
Relapsed/refractory acute lymphoblastic leukemia;
Safety;
Short-term effectiveness
- MeSH:
Male;
Child;
Female;
Humans;
Adolescent;
Antineoplastic Agents;
Retrospective Studies;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Antibodies, Bispecific/adverse effects*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(4):374-380
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia (R/R-ALL).
METHODS:Six children with R/R-ALL who received blinatumomab treatment from August 2021 to August 2022 were included as subjects, and a retrospective analysis was performed for their clinical data.
RESULTS:Among the six children, there were three boys and three girls, with a median age of 10.5 (5.0-13.0) years at the time of inclusion. Of all six children, one had refractory ALL and did not achieve remission after several times of chemotherapy, and 5 relapsed for the first time, with a median time of 30 (9-60) months from diagnosis to relapse. Minimal residual disease (MRD) before treatment was 15.50% (0.08%-78.30%). Three children achieved complete remission after treatment, among whom two had negative conversion of MRD. Five children had cytokine release syndrome (CRS), among whom 3 had grade 1 CRS and 2 had grade 2 CRS. Four children were bridged to allogeneic hematopoietic stem cell transplantation, with a median interval of 50 (40-70) days from blinatumomab treatment to transplantation. The six children were followed up for a median time of 170 days, and the results showed an overall survival rate of 41.7% (95%CI: 5.6%-76.7%) and a median survival time of 126 (95%CI: 53-199) days.
CONCLUSIONS:Blinatumomab has good short-term safety and effectiveness in the treatment of childhood R/R-ALL, and its long-term effectiveness needs to be confirmed by studies with a larger sample size.
